CA3041016C - Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles - Google Patents

Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles Download PDF

Info

Publication number
CA3041016C
CA3041016C CA3041016A CA3041016A CA3041016C CA 3041016 C CA3041016 C CA 3041016C CA 3041016 A CA3041016 A CA 3041016A CA 3041016 A CA3041016 A CA 3041016A CA 3041016 C CA3041016 C CA 3041016C
Authority
CA
Canada
Prior art keywords
estetrol
component
dysmenorrhea
estetrol component
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3041016A
Other languages
English (en)
Other versions
CA3041016A1 (fr
Inventor
Maud JOST
Glwadys RAUSIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Estetra SRL
Original Assignee
Estetra SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estetra SRL filed Critical Estetra SRL
Priority to CA3178291A priority Critical patent/CA3178291A1/fr
Publication of CA3041016A1 publication Critical patent/CA3041016A1/fr
Application granted granted Critical
Publication of CA3041016C publication Critical patent/CA3041016C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode de prise en charge de la dysménorrhée, consistant à administrer un composant strogénique qui est de préférence sélectionné dans le groupe constitué par l'estétrol et des composés de type estétrol. Étonnamment, les composés de type estétrol se sont révélés aptes à atténuer la dysménorrhée, lorsqu'ils sont utilisés seuls ou combinés à des composés progestatifs, dans une mesure qui dépasse l'effet obtenu avec d'autres compositions, et avec un profil d'effets secondaires avantageux par rapport aux méthodes actuellement disponibles.
CA3041016A 2016-08-05 2016-10-28 Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles Active CA3041016C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3178291A CA3178291A1 (fr) 2016-08-05 2016-10-28 Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2016/076104 WO2018065076A1 (fr) 2016-10-28 2016-10-28 Méthode de prise en charge de la dysménorrhée et des douleurs menstruelles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3178291A Division CA3178291A1 (fr) 2016-08-05 2016-10-28 Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles

Publications (2)

Publication Number Publication Date
CA3041016A1 CA3041016A1 (fr) 2018-04-12
CA3041016C true CA3041016C (fr) 2023-09-05

Family

ID=57209484

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3041016A Active CA3041016C (fr) 2016-08-05 2016-10-28 Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles

Country Status (5)

Country Link
JP (1) JP2018533542A (fr)
KR (1) KR20190076014A (fr)
AU (1) AU2016425935B2 (fr)
CA (1) CA3041016C (fr)
WO (1) WO2018065076A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2383279A1 (fr) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Procédé de préparation d'estetrol
EP3701944B1 (fr) 2015-06-18 2021-12-08 Estetra SRL Unité posologique orodispersible contenant un composant d'estétrol
CN116077454A (zh) 2015-06-18 2023-05-09 埃斯特拉有限责任公司 含雌四醇组分的口腔分散剂量单位
DK3310345T3 (da) 2015-06-18 2021-05-25 Estetra Sprl Orodispersibel tablet indeholdende estetrol
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
EP3749327A1 (fr) 2018-02-07 2020-12-16 Estetra SPRL Composition contraceptive présentant des effets cardiovasculaires réduits
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
IT202000003964A1 (it) * 2020-02-26 2021-08-26 Umberto Cornelli Composizione farmaceutica per l’uso nel trattamento di dismenorrea e/o sindrome premestruale
CN116669732A (zh) * 2021-02-02 2023-08-29 广州沪同有梧生物科技有限公司 Pqq及其衍生物的新应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO2012055840A1 (fr) * 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition et préparation pour le traitement de la dysménorrhée et de la douleur menstruelle et utilisation d'un agent hormonal et d'un sel de zinc pour le traitement de troubles menstruels
KR20220144885A (ko) * 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법

Also Published As

Publication number Publication date
KR20190076014A (ko) 2019-07-01
JP2018533542A (ja) 2018-11-15
CA3041016A1 (fr) 2018-04-12
WO2018065076A1 (fr) 2018-04-12
AU2016425935B2 (en) 2023-01-19
AU2016425935A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
AU2022231672B2 (en) Method for the management of dysmenorrhea and menstrual pain
CA3041016C (fr) Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles
RU2169567C2 (ru) Способ контрацепции женщин репродуктивного возраста, не достигших предменопаузы
KR101812160B1 (ko) 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리
US20200046729A1 (en) Methods using combined oral contraceptive compositions with reduced cardiovascular effects
NZ262657A (en) Hormone replacement therapy using estrogen and antiprogestin
IL187471A (en) Quadraphasic continuous graduated estrogen contraceptive
EP1796725B1 (fr) Traitement ou prevention des hemorragies occasionnelles chez les femmes sous progestogenotherapie
JP2007533681A (ja) 天然エストロゲンに基づく段階型避妊製剤
Von Schoultz Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment
JP2008527018A (ja) 避妊用医薬製剤
JPH08508502A (ja) 骨粗しょう症の治療方法および治療用組成物
US20080280861A1 (en) Method of Female Contraception and a Kit For Use Therein
Burkman Chapter Hormonal Contraception

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210504

EEER Examination request

Effective date: 20210504

EEER Examination request

Effective date: 20210504

EEER Examination request

Effective date: 20210504

EEER Examination request

Effective date: 20210504

EEER Examination request

Effective date: 20210504

EEER Examination request

Effective date: 20210504